Private company

Oyster Point Pharma, Inc.

Oyster Point Pharma, Inc. is an American biological products company, incorporated in Delaware.1 It is headquartered in Princeton, New Jersey.1

Last updated Oct 20, 2026.

Overview

  • IndustryBiological Products, (No Diagnostic Substances)1
  • HeadquartersPrinceton, New Jersey1
  • Incorporated inDE2
  • Business address202 Carnegie Center, Suite 106, Princeton, Nj 085402
  • Filer category, Emerging growth company2

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2021

-393.9%Operating margin3
-410.2%Net margin3
-101.1%Return on equity3
0.90×Debt to equity3
-$90.9MFree cash flow3

Where the money goes

Where each dollar of revenue went, fiscal 2021

  • Cost of revenue5¢$1.5M
  • Research and development82¢$24.2M
  • Interest13¢$3.7M

Out of $24.5M in revenue.3 The company lost money this year.

Financial statements

Revenue3$24.5M in 2021
0$10.0M$20.0M$30.0M2020: $0$020202021: $24.5M$24.5M2021
Operating income453-$96.7M in 2021+478% since 2018
-$100.0M-$75.0M-$50.0M-$25.0M02018: -$16.7M-$16.7M20182019: -$47.3M-$47.3M2019+183%2020: -$71.0M-$71.0M2020+50%2021: -$96.7M-$96.7M2021+36%
Net income453-$100.7M in 2021+510% since 2018
-$150.0M-$100.0M-$50.0M02018: -$16.5M-$16.5M20182019: -$45.7M-$45.7M2019+177%2020: -$70.5M-$70.5M2020+54%2021: -$100.7M-$100.7M2021+43%
Fiscal year20172018201920202021
Revenue$03$24.5M3
Cost of revenue$03$1.5M3
Research and development$13.8M4$33.6M5$39.8M3$24.2M3
Operating expenses$119.7M3
Operating income-$16.7M4-$47.3M5-$71.0M3-$96.7M3
Interest$03$3.7M3
Income tax$04$05$03$03
Net income-$16.5M4-$45.7M5-$70.5M3-$100.7M3
Earnings per share-$2.923-$3.873
Earnings per share (diluted)-$2.923-$3.873
Shares (weighted, basic)26.0M shares3
Shares (weighted, diluted)26.0M shares3

Compare Oyster Point Pharma, Inc. with another company

Corporate structure

Oyster Point Pharma, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Oyster Point Pharma, Inc.

  • Paradigm Biocapital Advisors LP Filed SC 13G/A on Oyster Point Pharma, Inc., latest Feb 14, 2023 (2 filings since Jul 18, 2022)
  • Point72 Asset Management, L.P. Filed SC 13G/A on Oyster Point Pharma, Inc., latest Feb 14, 2023 (3 filings since Oct 28, 2021)
  • RTW INVESTMENTS, LP Filed SC 13G/A on Oyster Point Pharma, Inc., latest Feb 14, 2023 (2 filings since Feb 14, 2022)
  • Versant Venture Capital VI, L.P. Filed SC 13D/A on Oyster Point Pharma, Inc., latest Jan 13, 2023 (3 filings since Oct 27, 2021)
  • New Enterprise Associates 14, L.P. Filed SC 13D/A on Oyster Point Pharma, Inc., latest Jan 9, 2023 (2 filings since Nov 21, 2022)
  • InvOpps IV US, L.P. Filed SC 13D/A on Oyster Point Pharma, Inc., latest Jan 5, 2023 (2 filings since Dec 21, 2022)
  • Wellington Management Company Filed SC 13G/A on Oyster Point Pharma, Inc., latest Feb 4, 2022
  • Oyster Point Pharma, Inc. Princeton, New Jersey

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Oyster Point Pharma, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$2.7M3 Dec 31, 2021$900.0K3 Dec 31, 2020+203.8%
Accumulated depreciation$237.0K3 Dec 31, 2021$96.0K3 Dec 31, 2020+146.9%
Property and equipment, net$2.5M3 Dec 31, 2021$804.0K3 Dec 31, 2020+210.6%
Finance-lease assets$18.0K3 Dec 31, 2021$34.0K3 Dec 31, 2020−47.1%
Operating-lease assets (leased space)$2.9M3 Dec 31, 2021$644.0K3 Dec 31, 2020+347.8%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$193.4M3 Dec 31, 2021$192.6M3 Dec 31, 2020+0.4%
Long-term investments$886.0K3 Dec 31, 2021$03 Dec 31, 2020

Inventory

ItemLatestA year beforeChange
Inventory, total$6.1M3 Dec 31, 2021$03 Dec 31, 2020
Raw materials$2.5M3 Dec 31, 2021
Work in process$3.1M3 Dec 31, 2021
Finished goods$509.0K3 Dec 31, 2021

Leadership

Who has led Oyster Point Pharma, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Jeffrey Nau2019–2023

President

  1. Jeffrey Nau2019–2023

Chief financial officer

  1. Daniel Lochner2019–2023
20202025
Board members and other officers (15)

Timeline

  1. Jan 13, 20238-K Ended a material agreement; Completed an acquisition or sale; Listing notice or transfer21
  2. Jan 3, 20238-K Ended a material agreement; Completed an acquisition or sale; Listing notice or transfer22
  3. Nov 10, 20228-K Results of operations23
  4. Nov 8, 20228-K Entered a material agreement24
  5. Nov 7, 20228-K Other events25
  6. Aug 11, 20228-K Results of operations26
  7. Jul 12, 20228-K Executive or director change27
  8. Jun 28, 20228-K Exit or restructuring costs; Executive or director change; Other events28
  9. Jun 8, 20228-K Shareholder vote29
  10. May 5, 20228-K Results of operations30
  11. Mar 18, 20228-K Executive or director change31
  12. Feb 24, 20228-K Results of operations32
  13. Oct 30, 2019New chief executive Jeffrey Nau becomes CEO8

Calendar

When it reported results

  1. Nov 10, 2022Reported quarterly or annual results23
  2. Aug 11, 2022Reported quarterly or annual results26
  3. May 5, 2022Reported quarterly or annual results30
  4. Feb 24, 2022Reported quarterly or annual results32
  5. Nov 4, 2021Reported quarterly or annual results33

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

95 filings to the SEC since October 2021: 1 annual reports, 4 quarterly reports, 16 major events, 40 insider forms, 15 large holders, 19 other. The latest 20:

  1. Feb 14, 2023SC 13G/A EDGAR
  2. Feb 14, 2023SC 13G/A OYSTER POINT PHARMA, INC. EDGAR
  3. Feb 14, 2023SC 13G/A SCHEDULE 13G/A, AMENDMENT #2 EDGAR
  4. Jan 13, 202315-12G EDGAR
  5. Jan 13, 20238-K/A EDGAR
  6. Jan 13, 2023SC 13D/A EDGAR
  7. Jan 9, 2023SC 13D/A NEW ENTERPRISE ASSOCIATES 14, L.P. -- OYSTER POINT PHARMA, INC. 13D/A(#2E) EDGAR
  8. Jan 5, 2023EFFECT EDGAR
  9. Jan 5, 2023SC 13D/A EDGAR
  10. Jan 5, 20234 FORM 4 SUBMISSION EDGAR
  11. Jan 4, 20234 FORM 4 SUBMISSION EDGAR
  12. Jan 4, 20234 FORM 4 SUBMISSION EDGAR
  13. Jan 4, 20234 FORM 4 SUBMISSION EDGAR
  14. Jan 4, 20234 FORM 4 SUBMISSION EDGAR
  15. Jan 4, 20234 FORM 4 SUBMISSION EDGAR
  16. Jan 4, 20234 FORM 4 SUBMISSION EDGAR
  17. Jan 4, 20234 FORM 4 SUBMISSION EDGAR
  18. Jan 4, 20234 FORM 4 SUBMISSION EDGAR
  19. Jan 4, 20234 FORM 4 SUBMISSION EDGAR
  20. Jan 4, 20234 FORM 4 SUBMISSION EDGAR

The 95 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

3 open-market trades by officers, directors and large owners since October 2021: 0 buys and 3 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Oct 18, 2021LINK WILLIAM J PHDDirectorSale550,000$14.83$8.2MForm 4
Oct 18, 2021Versant Venture Capital VI, L.P.10% ownerSale550,000$14.83$8.2MForm 4
Oct 18, 2021Ozawa ClareDirectorSale550,000$14.83$8.2MForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How Oyster Point Pharma, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGAROyster Point Pharma, Inc.1
  • CIK0001720725
  • Employer ID (EIN)81-10309551
  • Filer status<br>emerging growth company1
  • Incorporated inDelaware1
  • Fiscal year endsDecember 311
  • Industry code (SIC)2836 Biological Products, (No Diagnostic Substances)1
  • Business address202 Carnegie Center, Suite 106, Princeton, NJ 085401
  • Phone(609) 382-90321
  • Shares outstanding26,844,292 as of Nov 4, 20227
  • Public float$214.6M as of Jun 30, 20213
  • On EDGAR sinceOct 25, 20171
  • Filings280 in all: 4 (101), 8-K (41), 3 (23), CORRESP (11), 10-Q (10), SC 13D/A (10), SC 13G/A (7), UPLOAD (5)1
    All 42 form types

    DEF 14A (4), EFFECT (4), S-8 (4), S-8 POS (4), SC 13G (4), SC14D9C (4), 10-K (3), 4/A (3), S-1/A (3), SC 13D (3), SC 14D9/A (3), SC TO-C (3), 424B4 (2), D (2), DEFA14A (2), DRS (2), S-1 (2), SC 14D9 (2), SC TO-T/A (2), SEC STAFF LETTER (2), 15-12G (1), 25-NSE (1), 424B5 (1), 8-A12B (1), 8-K/A (1), CERT (1), DRS/A (1), DRSLTR (1), FWP (1), POS AM (1), POS EX (1), S-1MEF (1), S-3 (1), SC TO-T (1)

  • Latest filingsAnnual report (10-K) Feb 24, 2022
    Quarterly report (10-Q) Nov 10, 2022
    Proxy statement (DEF 14A) Apr 22, 2022
    Latest 8-K (8-K) Jan 3, 2023

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
    SEC EDGAROther events
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40